Arbaclofen for stiffness (spasticity) in multiple sclerosis
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This Phase 3 study tests arbaclofen extended-release tablets to reduce spasticity (painful muscle stiffness) in people with multiple sclerosis. If it works, it may make it easier to move and improve day-to-day comfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have a confirmed multiple sclerosis diagnosis and spasticity for at least 6 months
- Your stiffness/spasms are mainly due to MS and meet the trial’s spasticity score (TNmAS-MAL)
- Your disability score (EDSS) is between 3.0 and 7.0
- You’re willing to sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether wearing a special suit at home can help manage muscle stiffness (spasticity) or lack of coordination (ataxia) caused by multiple sclerosis. The suit delivers gentle stimulation to improve movement in your arms or legs.
This study looks at patterns of muscle stiffness (spasticity) in people with multiple sclerosis and how these patterns affect daily life and well-being. It aims to better understand the link between spasticity and quality of life.
This trial tests whether IPN10200, a Botox-like treatment, is safe and helps reduce stiff, tight upper-arm muscles caused by spasticity after stroke or brain injury. You may be able to join if you meet specific timing, prior-treatment, and muscle-stiffness measurements.
This study tests a medicine called arbaclofen to see how it affects brain waves in people with autism. It includes a brief double-blind crossover phase followed by a 10-week open-label treatment period.
This study tests an investigational drug (BMS-986368) to see if it helps reduce muscle stiffness and spasms caused by multiple sclerosis. It may be an option if you have had spasticity for at least 6 months and are not currently using other treatments that cannot be paused.
This Phase 2 trial tests whether cannabis can reduce muscle stiffness (spasticity) in people with multiple sclerosis. You may be able to participate if your stiffness is not improving with your current treatments.
Hear when a new Spasticity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.